Literature DB >> 29059466

Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality.

Christian Jansen1, Philipp Möller1, Carsten Meyer2, Carl Christian Kolbe3, Christopher Bogs1, Alessandra Pohlmann1, Robert Schierwagen1, Michael Praktiknjo1, Zeinab Abdullah4, Jennifer Lehmann1, Daniel Thomas2, Christian P Strassburg1, Eicke Latz3,5, Sebastian Mueller6, Martin Rössle7, Jonel Trebicka1,8,9,10.   

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) efficiently treats complications of portal hypertension. Liver and spleen stiffness might predict clinically significant portal hypertension. This prospective study investigated liver stiffness in patients receiving TIPS regardless of indication. Of 83 included patients, 16 underwent transient elastography immediately before and 30 minutes after TIPS (acute group), while 67 received shear wave elastography of liver and spleen 1 day before and 7 days after TIPS (chronic group) and were followed further. In blood samples obtained before TIPS from cubital, portal, and hepatic veins, levels of several interleukins (IL1b, IL6, IL8, IL10, IL18) and interferon-gamma were analyzed. In 27 patients (5 acute, 22 chronic), it resulted in an increase in liver stiffness of >10%. In 56 patients, liver stiffness decreased or remained unchanged (<10%). Importantly, spleen stiffness measured by shear wave elastography decreased in all patients (chronic group). None of the clinical or laboratory parameters differed between patients with increase in liver stiffness and those without. Of note, patients with increased liver stiffness showed higher overall and/or hepatic venous levels of proinflammatory cytokines at TIPS and higher incidence of organ failure and worse survival after TIPS. C-reactive protein values and increase of >10% in liver stiffness after TIPS were the only independent predictors of mortality in these patients.
CONCLUSION: This study demonstrates that the presence of systemic inflammation predisposes patients to develop increased liver stiffness after TIPS, a predictor of organ failure and death. (NCT03072615) (Hepatology 2018;67:1472-1484).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29059466     DOI: 10.1002/hep.29612

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

Review 2.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

3.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

Review 4.  Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

Authors:  Jonel Trebicka; Thomas Reiberger; Wim Laleman
Journal:  Visc Med       Date:  2018-07-13

Review 5.  Managing portal hypertension in patients with liver cirrhosis.

Authors:  Tilman Sauerbruch; Robert Schierwagen; Jonel Trebicka
Journal:  F1000Res       Date:  2018-05-02

6.  Advances and challenges in cirrhosis and portal hypertension.

Authors:  Annalisa Berzigotti
Journal:  BMC Med       Date:  2017-11-10       Impact factor: 8.775

7.  Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis.

Authors:  Jonel Trebicka; Alex Amoros; Carla Pitarch; Esther Titos; José Alcaraz-Quiles; Robert Schierwagen; Carmen Deulofeu; Javier Fernandez-Gomez; Salvatore Piano; Paolo Caraceni; Karl Oettl; Elsa Sola; Wim Laleman; Jane McNaughtan; Rajeshwar P Mookerjee; Minneke J Coenraad; Tania Welzel; Christian Steib; Rita Garcia; Thierry Gustot; Miguel A Rodriguez Gandia; Rafael Bañares; Agustin Albillos; Stefan Zeuzem; Victor Vargas; Faouzi Saliba; Frederic Nevens; Carlo Alessandria; Andrea de Gottardi; Heinz Zoller; Pere Ginès; Tilman Sauerbruch; Alexander Gerbes; Rudolf E Stauber; Mauro Bernardi; Paolo Angeli; Marco Pavesi; Richard Moreau; Joan Clària; Rajiv Jalan; Vicente Arroyo
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

8.  Exploring Interactions between Primary Hepatocytes and Non-Parenchymal Cells on Physiological and Pathological Liver Stiffness.

Authors:  Vaishaali Natarajan; Youra Moeun; Srivatsan Kidambi
Journal:  Biology (Basel)       Date:  2021-05-05

9.  The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease.

Authors:  Robert Schierwagen; Frank E Uschner; Cristina Ortiz; Sandra Torres; Max J Brol; Olaf Tyc; Wenyi Gu; Christian Grimm; Stefan Zeuzem; Andreas Plamper; Philipp Pfeifer; Sebastian Zimmer; Christoph Welsch; Liliana Schaefer; Karl P Rheinwalt; Joan Clària; Vicente Arroyo; Jonel Trebicka; Sabine Klein
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

10.  Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis.

Authors:  Michael Praktiknjo; Robert Schierwagen; Sofia Monteiro; Cristina Ortiz; Frank Erhard Uschner; Christian Jansen; Joan Claria; Jonel Trebicka
Journal:  Gut       Date:  2020-10-21       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.